Who is sponsoring NCT00411125?

NCT00411125 is sponsored by Novartis.

What condition does NCT00411125 study?

NCT00411125 studies Postmenopausal Osteoporosis.

What drugs are being tested in NCT00411125?

Interventions: Oral salmon calcitonin.

What is the status of NCT00411125?

NCT00411125 is currently COMPLETED.

Last reviewed 2006-12-11 · How we verify

A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled Crossover Phase I Study Assessing Pharmacokinetics and Pharmacodynamics of Two Different SMC021 0.8 mg Variants and the Effect of Timing of Drug Intake in Healthy Postmenopausal Women

NCT00411125 Phase 1 COMPLETED

This is a phase I study to analyze bioavailability and pharmacodynamic of two different variants of oral salmon calcitonin (SMC021) in postmenopausal women

Details

Lead sponsor	Novartis
Phase	Phase 1
Status	COMPLETED
Enrolment	86
Start date	2006-08
Completion	2006-11

Conditions

Postmenopausal Osteoporosis

Interventions

Oral salmon calcitonin

Primary outcomes

Pharmacokinetic profile of the new variant compared to the current variant on Day 1
Effect on bone resorption biomarker on Day 1

Countries

Denmark